Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Tr. 2012;133:831–41.

Article  Google Scholar 

Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage i and ii breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97.

Article  CAS  PubMed  Google Scholar 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New Engl J Med. 2017;377:1836–46.

Article  PubMed  Google Scholar 

Fillon M. Breast cancer recurrence risk can remain for 10 to 32 years. Ca Cancer J Clin. 2022;72:197–9.

Article  PubMed  Google Scholar 

Reymond N, d’Água BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013;13:858–70.

Article  CAS  PubMed  Google Scholar 

Riethdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann Ny Acad Sci. 2010;1210:66–77.

Article  CAS  PubMed  Google Scholar 

Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer. 2017;16:176.

Article  PubMed  PubMed Central  Google Scholar 

Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A. AJCC cancer staging manual seventh edition. In: Part VII: Breast 7th. New York, Dordrecht, Heidelberg, London: Springer; 2010. p. 345–76.

Google Scholar 

Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet. 2019;95:643–60.

Article  CAS  PubMed  Google Scholar 

Pondé NF, Zardavas D, Piccart M. Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2019;16:27–44.

Article  PubMed  Google Scholar 

Perumal V, Corica T, Dharmarajan AM, Sun Z, Dhaliwal SS, Dass CR, et al. Circulating tumour cells (CTC), head and neck cancer and radiotherapy; future perspectives. Cancers. 2019;11:367.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298–306.

Article  PubMed  PubMed Central  Google Scholar 

Habli Z, AlChamaa W, Saab R, Kadara H, Khraiche ML. Circulating tumor cell detection technologies and clinical utility: challenges and opportunities. Cancers. 2020;12:1930.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409–24.

Article  CAS  PubMed  Google Scholar 

Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem. 2011;57:421–30.

Article  CAS  PubMed  Google Scholar 

der Auwera IV, Peeters D, Benoy IH, Elst HJ, Laere SJV, Prové A, et al. Circulating tumour cell detection: a direct comparison between the Cell Search System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer. Brit J Cancer. 2010;102:276–84.

Article  PubMed  Google Scholar 

Eslami-S Z, Cortés-Hernández LE, Alix-Panabières C. Epithelial cell adhesion molecule: an anchor to isolate clinically relevant circulating tumor cells. Cells. 2020;9:1836.

Article  PubMed  PubMed Central  Google Scholar 

Tjensvoll K, Nordgård O, Skjæveland M, Oltedal S, Janssen EAM, Gilje B. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. BMC Cancer. 2019;19:1131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bankó P, Lee SY, Nagygyörgy V, Zrínyi M, Chae CH, Cho DH, et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol. 2019;12:48.

Article  PubMed  PubMed Central  Google Scholar 

Millner LM, Linder MW, Valdes R. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013;43:295–304.

CAS  PubMed  PubMed Central  Google Scholar 

Ignatiadis M, Reinholz M. Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res. 2011;13:222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. Jnci J National Cancer Inst. 2014;106:dju066.

Article  Google Scholar 

Sparano J, O’Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, et al. Association of circulating tumor cells with late recurrence of estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. Jama Oncol. 2018;4:1700.

Article  PubMed  PubMed Central  Google Scholar 

Matikas A, Kotsakis A, Apostolaki S, Politaki H, Perraki M, Kalbakis K, et al. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Brit J Cancer. 2022;126:1563–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. Jnci J National Cancer Inst. 2018;111:380–7.

Article  Google Scholar 

Pierga J-Y, Petit T, Lévy C, Ferrero J-M, Campone M, Gligorov J, et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin Cancer Res. 2015;21:1298–304.

Article  CAS  PubMed  Google Scholar 

Goodman CR, Seagle B-LL, Friedl TWP, Rack B, Lato K, Fink V, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. Jama Oncol. 2018;4:e180163–e180163.

Article  PubMed  PubMed Central  Google Scholar 

Cesca MG. Circulating tumor cells and treatment de-escalation after neoadjuvant therapy for HER2 positive breast cancer (HER2Cell) ClinicalTrials.gov Identifier: NCT04993014. Updated August 6, 2021. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04993014.

Tredan O. Evaluate the clinical benefit of a post-operative treatment associating radiotherapy + nivolumab + ipilimumab versus radiotherapy + capecitabine for triple negative breast cancer patients with residual disease (BreastImmune03). ClinicalTrials.gov Identifier: NCT03818685. Updated July 22, 2022 [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03818685.

Mäurer M. Association of adjuvant radiotherapy of non-metastatic breast carcinoma with immunomodulation and circulating tumor cell phenotype in relation to patient age (CETC). ClinicalTrials.gov Identifier: NCT04 902937. Updated: Nov 8, 2022. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04902937

Li J. CTC changes and efficacy of neoadjuvant chemotherapy for triple-negative breast cancer [Internet]. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04059003

Yin W. CTCs in breast cancer after neoadjuvant treatment and surgery: a multicenter, prospective clinical trial (CTCNeoBC-E) [Internet]. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT05360290

Ouyang Q. Evaluation of treatment efficacy by circulating tumor cell phenotype surveillance in breast cancer patients. ClinicalTrials.gov Identifier: NCT05326295. Updated April 13, 2022. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT05326295.

Jerzak KJ. Genomic markers for measuring breast cancer response to neoadjuvant chemotherapy. ClinicalTrials.gov Identifier: NCT03709134. Updated October 14, 2021. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03709134.

Li J. Circulating tumor cell detection in patients with luminal a breast cancer. ClinicalTrials.gov Identifier: NCT04065321. Updated May 5, 2022. [cited 2023 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04065321.

Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of circulating tumour cells. Nat Rev Cancer. 2023;23:95–111.

Article  CAS  PubMed  Google Scholar 

Choi JW, Kim JK, Yang YJ, Kim P, Yoon K-H, Yun SH. Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells. Cancer Res. 2015;75:4474–82.

Article  CAS  PubMed  Google Scholar 

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9:1773–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parkins KM, Dubois VP, Kelly JJ, Chen Y, Knier NN, Foster PJ, et al. Engineering circulating tumor cells as novel cancer theranostics. Theranostics. 2020;10:7925–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwarzenbach H, Pantel K. Circulating DNA as biomarker in breast cancer. Breast Cancer Res. 2015;17:136.

Article  PubMed  PubMed Central  Google Scholar 

Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA, et al. Commercial ctDNA assays for minimal residual disease detection of solid tumors. Mol Diagn Ther. 2021;25:757–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agassi R, Czeiger D, Shaked G, Avriel A, Sheynin J, Lavrenkov K, et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast